 |
市場調查報告書
商品編碼
1149803
降血糖藥市場：按藥物類別、給藥途徑、分銷渠道、地區 - 規模、份額、前景和機會分析，2022-2030 年Hypoglycemic Drugs Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 |
||||||
價格
簡介目錄
低血糖症是指血糖（葡萄糖）水平低於正常水平的情況。葡萄糖是身體的主要能量來源。低血糖通常與糖尿病治療有關。當血液中的葡萄糖濃度低於設定點，即低於 4mmol/L (72mg/dL) 時，就會發生低血糖症。與低血糖相關的症狀包括出汗、疲勞、頭暈、虛弱和視力模糊。通過使用血糖儀測量血糖水平來檢測低血糖症。血糖水平低於 4.0 mmol/L 表示低血糖。
市場動態
預計糖尿病患者數量的增加將推動全球降糖藥市場的增長。例如，根據美國糖尿病協會 2022 年 7 月 28 日發表的一篇文章，2019 年有 3730 萬美國人（佔人口的 11.3%）患有糖尿病。約有 190 萬美國人患有 1 型糖尿病，其中約有 244,000 人是兒童和青少年。每年有 140 萬美國人被診斷患有糖尿病。根據同一個 Sorus 的數據，在 2014-2015 年，青少年中確診糖尿病的年發病率估計為 18,200 例 1 型糖尿病和 5,800 例 2 型糖尿病。
監管機構批准的藥物數量不斷增加，預計將推動全球降糖藥物市場的增長。例如，2020 年 12 月，專業製藥公司 Anfastar Pharmaceuticals, Inc. 宣布美國食品藥品監督管理局 (FDA) 已批准其胰高血糖素注射急救試劑盒 1mg 的簡化新藥申請。胰高血糖素適用於治療嚴重的低血糖症，也可用作輔助診斷。
這項研究的主要特點
- 本報告對全球降糖藥市場進行了深入分析，提供了以 2021 年為基準年的預測期 (2022-2030) 的市場規模和復合年增長率 (CAGR%)。.
- 它揭示了不同細分市場的潛在收入機會，並描述了該市場具有吸引力的投資建議矩陣。
- 它還提供了有關市場驅動因素、限制因素、機會、新藥發布和批准、區域前景以及主要參與者採用的競爭戰略的重要見解。
- 根據公司概況、業績、產品組合、地域分佈、分銷戰略、主要發展和戰略以及未來計劃等參數，對全球降糖藥市場的主要參與者進行了概況分析。
- 本次調查涵蓋的主要公司包括 Eli Lilly & Company、Boehringer Ingelheim GmbH、Vistin Pharma AS、Janssen Pharmaceuticals NV、Sanofi、Astellas Pharma Inc.、AstraZeneca plc.、Merck & Co., Inc.、Novartis AG、 Novo Nordisk A/S、Teva Pharmaceuticals Pvt Ltd. 和 Sun Pharmaceutical Industries Ltd.
- 這份報告中的見解將使公司的營銷人員和管理人員能夠就未來的產品發布、技術升級、市場擴張和營銷策略做出明智的決策。
- 本研究報告面向該行業的各種利益相關者，包括投資者、供應商、製造商、分銷商、新進入者和金融分析師。
- 利益相關者可以通過用於分析全球降糖藥市場的各種戰略矩陣來促進他們的決策。
內容
第 1 章目的和先決條件
- 調查目的
- 先決條件
- 縮寫說明
第 2 章市場概述
- 報告內容
- 市場定義和範圍
- 執行摘要
- 市場細分：按藥物類別
- 按給藥途徑細分的市場
- 按分銷渠道細分的市場
- 按地區劃分的市場細分
- 連貫機會圖 (COM)
第3章市場動態、規律及趨勢分析
- 市場動態
- 司機
- 約束因素
- 市場機會
- 影響分析
- 分銷商名單
- 主要發展狀況
- 害蟲分析
- 監管情景
- 新產品的發布和批准
- 收購和合作場景
- 市場趨勢
第 4 章全球降糖藥市場：冠狀病毒 (COVID-19) 大流行的影響
- 經濟影響
- COVID-19 的流行病學特徵
- 供需分析
第 5 章全球降糖藥市場：按藥物類別分類，2017-2030
- 磺尿類
- 雙胍類
- α-葡萄糖甘□抑製劑
- 塞唑烷二酮
- 二□基□□ 4 (DPP-4) 抑製劑
- 胰高血糖素
第 6 章全球降糖藥市場：按給藥途徑，2017-2030
- 口服劑
- 注射
- 鼻音
第 7 章全球降糖藥市場：分銷渠道，2017-2030
- 醫院藥房
- 零售藥房
- 在線藥店
第 8 章按地區分列的全球降糖藥市場，2017-2028
- 北美
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲地區
- 歐洲
- 德國
- 英國
- 法國
- 意大利
- 西班牙
- 俄羅斯
- 其他歐洲地區
- 亞太地區
- 中國
- 印度
- 日本
- 澳大利亞
- 韓國
- 東盟
- 其他亞太地區
- 中東
- 海灣合作委員會
- 以色列
- 其他中東地區
- 非洲
- 南非
- 中非
- 北非
第9章競爭格局
- 公司簡介
- Eli Lilly & Company
- Boehringer Ingelheim GmbH
- Vistin Pharma AS
- Janssen Pharmaceuticals NV
- Sanofi
- Astellas Pharma Inc.
- AstraZeneca plc.
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Teva Pharmaceutical Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
第 10 章
- 參考資料
- 調查方法
簡介目錄
Product Code: CMI5252
Hypoglycemia is a condition in which blood sugar (glucose) level is lower than the standard range. Glucose is the main energy soiurce for the body. Hypoglycemia is often related to diabetes treatment. Hypoglycemia occurs when the level of glucose present in the blood falls below a set point, i.e., below 4 mmol/L (72mg/dL). The symptoms associated with Hypogyclemia are, sweating, fatigue, feeling dizzy, feeling weak, blurred vision, and others. Hypoglycemia is detected by measuring blood sugar levels with a glucose meter. Any blood glucose level below 4.0 mmol/L indicates that the individual has hypoglycemia.
Market Dynamics
Increasing prevalence of diabetes is expected to drive growth of the global hypoglycemic drugs market. For instance, according to an article published by American Diabetes Association on 28 July 2022, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents. 1.4 million Americans are diagnosed with diabetes every year.according to same soruce, In 2014-2015, the annual incidence of diagnosed diabetes in youth was estimated at 18,200 with type 1 diabetes and 5,800 with type 2 diabetes.
Increasing number of drug approvals from regulatory bodies is expected to drive growth of the global hypoglycemic drugs market. For instance, in December 2020, Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid.
Key features of the study:
- This report provides an in-depth analysis of the global hypoglycemic drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global hypoglycemic drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceuticals NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global hypoglycemic drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global hypoglycemic drugs market
Detailed Segmentation:
- Global Hypoglycemic Drugs Market, By Drug Class:
- Sulphonylureas
- Biguanides
- Alpha-glucosidase inhibitors
- Thiazolidinediones (Glitazones)
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Glucagon
- Global Hypoglycemic Drugs Market, By Route of Administration:
- Oral
- Injectable
- Nasal
- Global Hypoglycemic Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hypoglycemic Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Eli Lilly & Company*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boehringer Ingelheim GmbH
- Vistin Pharma AS
- Janssen Pharmaceuticals NV
- Sanofi
- Astellas Pharma Inc.
- AstraZeneca plc.
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Teva Pharmaceuticals Pvt Ltd.
- Sun Pharmaceutical Industries Ltd.
- Eli Lilly & Company*
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- List of Distributors
- Key Developments
- PEST Analysis
- Regulatory Scenario
- New Product Launch/ Approval
- Acquisition and Partnership Scenario
- Market Trends
4. Global Hypoglycemic Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Supply and Demand Analysis
5. Global Hypoglycemic Drugs Market, By Drug Class, 2017-2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Sulphonylureas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Biguanides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Alpha-glucosidase inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Thiazolidinediones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Dipeptidyl Peptidase-4 (DPP-4) inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Glucagon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
6. Global Hypoglycemic Drugs Market, By Route of Administration, 2017-2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
7. Global Hypoglycemic Drugs Market, By Distribution Channel, 2017-2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
8. Global Hypoglycemic Drugs Market, By Region, 2017 - 2028 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country/ Region, 2017 - 2030 (US$ Mn)
- South Africa
- Central Africa
- North Africa
9. Competitive Landscape
- Company Profiles
- Eli Lilly & Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Boehringer Ingelheim GmbH
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Vistin Pharma AS
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Janssen Pharmaceuticals NV
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Astellas Pharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novo Nordisk A/S
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceutical Pvt. Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Analyst Views
10. Section
- References
- Research Methodology
- About Us and Sales Contact
